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Cytopenias are the most common HIV-associated hematological abnormality; they become 
more prevalent as HIV progresses and are often fatal. Cytopenias have been associated with 
demographic, clinical and physiological factors. Data from resource-limited settings about the 
prevalence and correlates of cytopenia, the trend in hematological parameters while on 
treatment and the association of these changes with clinical outcomes are limited. 
Methods 
These were secondary analyses of hematological data that was collected from 400 HIV-
infected subjects who were HAART-naïve or on HAART for ≤ 6 months and were enrolled 
into the Multivitamins, HAART and HIV/AIDS Trial in Uganda. Anemia was defined 
according to WHO guidelines while leucopenia and thrombocytopenia were defined using 
study-site-specific laboratory reference ranges for lack of generally accepted definitions. 
Univariate and bivariate analyses were done to describe the patient population and log-
binomial regression was used to quantify the correlates of cytopenia. Multi-level mixed 
effects linear regression models were used to investigate trends in and factors associated with 
change in hemoglobin and other selected hematological parameters over time. The 
association between anemia, disease progression and/or death was explored using log-
binomial regression models. 
Results 
At baseline, 65% of the 400 subjects had at least one form of cytopenia. Anemia occurred in 
47.8%, leucopenia in 24.3%, thrombocytopenia in 8.3%, bicytopenia (any 2 forms of 
cytopenia) in 21.9% and only 2 had a pancytopenia (all the 3 forms of cytopenia). Cytopenia 
 6 
 
was more prevalent in females, in subjects with lower CD4 cell count and those with lower 
body mass index (BMI).  
During follow-up, there were significant increases in hemoglobin levels, the mean 
corpuscular volume (MCV), white blood cell counts and the platelet counts. These changes in 
hematological parameters were associated with CD4 cell count, sex, BMI and age. The mean 
corpuscular hemoglobin (MCH) also increased over time although the absolute values 
remained within the normal range (24-35 picograms) while the mean corpuscular hemoglobin 
concentration (MCHC) was more or less the same. 
Conclusions 
Cytopenias are a frequent complication in HIV-infected adults at initiation of HAART in 
Uganda. Identifying risk factors for these abnormalities and pre-HAART interventions may 
ameliorate these complications. Further studies are needed to confirm the causal pathway 
between HIV burden, hematological manifestations and clinical outcomes. 
 
Keywords: Hematological abnormalities, HIV, Cytopenia, HAART, Uganda 
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1 Introduction and background 
1.1 HIV infection and pathogenesis 
HIV infection is transmitted through viral shedding at mucosal surface lesions in contact with 
infected body fluids such as blood, semen or vaginal secretions [1]. HIV entry into the host 
immune system is mainly through interactions between CD4 cells and the presence of 
chemokine coreceptors CCR5 and CXCR4[2, 3]. Other cells such as dendritic cells, 
monocytes and macrophages may be infected by HIV through CD4 and chemokine 
receptors[4]. However, viral uptake by some other cells may be independent of the presence 
of CD4 cells but rather mediated by other chemokines or viral proteins for example infection 
of astrocytes [5] and renal epithelial cells [6]. HIV transmission is initially followed by a 
rapid viral replication and activation of the immune system via leakage of the virus through 
the gastrointestinal tract mucosa into systemic circulation before reaching a viral set-point. 
This immune activation is characterized by the release of proinflammatory cytokines and 
chemokines, polyclonal B-cell activation and progressive CD4 depletion [7-9]. The chronic 
immune activation and inflammation may contribute to clinical progression [10, 11]. 
1.2 HIV-associated complications 
HIV infection has been associated with a broad range of clinical complications and 
hematological abnormalities are among the most common. HIV infection influences all 
hematopoietic cell lines leading to a spectrum of hematological abnormalities the most 
important and the most common of these being abnormalities affecting the cellular elements 
in peripheral blood known as cytopenias [12]. Other hematological complications may 
involve the bone marrow as well as the coagulation pathways. Cytopenias may be caused by 
increased destruction or reduced production of white blood cells (leucopenia or neutropenia), 
red blood cells (anemia) and platelets (thrombocytopenia). The causes of hematological 
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abnormalities in HIV are multi-factorial with several contributing factors [7, 10, 13, 14] and 
their frequency increases with disease progression [15]. 
1.3 Normal hematopoiesis 
Hematopoietic stem cells (HSCs) are rare self-renewing cells that reside in the bone marrow 
from which various types of blood cell lineages are produced. Hematopoiesis is the step-wise 
process by which HSCs generate multi-lineage progenitor cells that later commit to 
precursors of specific hematopoietic lineages and differentiate into mature blood cells: red 
blood cells, megakaryocytes, white blood cells and lymphoid cells [16, 17]. 
1.4 Pathogenetic mechanisms of cytopenias 
HIV infection may affect processes that are important during the early stages of 
hematopoiesis or stem cell differentiation leading to a spectrum of morphological changes 
within the bone marrow microenvironment that are strongly associated with various forms 
and levels of peripheral blood cytopenias [18, 19]. These hematologic abnormalities caused 
by altered stem cell differentiation reach far beyond the loss of CD4+ cells and could be due 
to abnormal lineage specific expression of certain cellular genes such as cytokines interleukin 
6 (IL-6) and granulocyte colony-stimulating factor that play a role in regulation of 
hematopoiesis [20]. HIV-1 induced hematopoietic suppression may be mediated by the HIV-
1 encoded envelope glycoprotein gp120, the extracellular viral accessory protein Negative 
factor (Nef) and cellular proteins such as tumor necrosis factor alpha. Soluble Nef has been 
shown to induce a transcriptional factor PRARγ in uninfected hematopoietic stem cells 
(HSCs) which in turn suppresses the expression of 2 other factors STAT5A and STAT5B that 
are necessary for proper functioning of HSCs [21]. HIV may directly infect the microvascular 
endothelial cells of the bone marrow and provide a continuous source of the virus [10]. This 
alters the cytokine levels thus affecting the stromal/progenitor cell microenvironment that 
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supports hematopoiesis. The release of viral proteins is thought to have cytotoxic effects on 
blood stem cells [22]. 
Comorbid opportunistic infections, neoplastic disorders, prolonged physiological stress, 
immune mediated factors and the cytotoxic effects of antiretroviral and antimicrobial therapy 
further confound the hematopoietic suppression making the causative role of HIV in vivo 
uncertain [13, 18]. The association of HIV-infection with hematological abnormalities is 
dependent on viral replication as the severity of these abnormalities increases with disease 
progression [21, 23]. Functional hematopoiesis may be restored or corrected by HAART [24, 
25] however; prolonged use of HAART may on the other hand contribute to the persistent 
hematopoietic suppression. HIV-associated anemia in particular may occur through three 
basic mechanisms affecting the red blood cells (RBC):  
Decreased RBC production resulting from infiltration of the bone marrow by infections 
including HIV itself, neoplasms, myelosuppressive drugs (including AZT), decreased 
production of endogenous erythropoietin or reduced response to erythropoietin and 
hypogonadism[4, 26-28]. 
Increased destruction of RBCs in the spleen or circulatory system by RBC autoantibodies, 
disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, glucose-6-
phosphate hydrogenase deficiency and medications [12, 17, 29, 30] and; 
Ineffective RBC production mainly as a result of nutritional deficiencies of iron, folic acid 
and vitamin B12 may be due to malabsorption in the ileum, gastric infections or other gastric 
mucosa pathology. Adverse effects of ARVs such as anemia, neutropenia and 
thrombocytopenia have been observed in HIV positive individuals before and after the 




1.5 Epidemiology of Cytopenia in the pre-HAART era 
In a pre-HAART series of patients with AIDS, anemia was noted in 70% of patients, 
lymphopenia in 70%, neutropenia in 50%, and thrombocytopenia in 40% and the prevalence 
of these abnormalities was found to increase with severity of clinical disease [15, 31]. 
Anemia was found to be the most common hematologic abnormality associated with HIV 
infection affecting 60-80% of patients with AIDS, 50% of those with early stage disease and 
18% of those who are asymptomatic  [27, 32]. Several studies have since documented the 
presence of anemia as an independent risk factor for mortality among HIV infected 
individuals [32-38]. The incidence of the various cytopenias correlates with the degree of 
immunosuppression and isolated abnormalities could be indications of HIV infection itself. 
Costello observed that the bone marrow cellularity in the HIV-infected patient did not always 
correlate with peripheral blood findings [31]. However, further studies showed that these 
hematologic abnormalities both in peripheral blood and the bone marrow particularly 
pancytopenia and marrow cellularity indicated the bone marrow as a target organ of drugs, 
immune mechanisms, opportunistic infections and the HI virus itself [39, 40]. 
1.6 Epidemiology of Cytopenia in the era of HAART 
Highly Active Anti-Retroviral Therapy (HAART) is the current standard of care for HIV-
infected individuals even in resource-limited settings and it has proven clinical and 
immunological benefits. The scale up of HAART has altered the expected natural history of 
HIV infection by reducing the frequency of opportunistic infections, hematologic 
complications and other AIDS-related malignancies [41, 42]. However, in some individuals 
optimum treatment response is not achieved while in others these potent drugs lead to adverse 
effects. With the increasing availability of HAART some of these adverse effects may mimic 
manifestations of HIV itself.  
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The magnitude of hematological abnormalities has been described as varying by region or 
country [43], degree of suppression of the virus and expected survival of infected individuals 
[21, 23] as well as the availability and accessibility to the various classes of these potent 
antiretroviral drugs [44-47]. A thorough assessment of the patient’s hematological profile is 
central to the clinician’s informed choice of an appropriate antiretroviral regimen and overall 
patient care [41, 46, 48]. 
Anemia is still the most common cytopenia in the era of ART and was frequently associated 
with the use of zidovudine (ZDV) or azidothymidine (AZT) during the early 1980s when 
these two drugs were  used in high doses as monotherapy for HIV infection [49]. In an early 
clinical trial of the efficacy of AZT in treatment of AIDS, it was found that there were 
significant reductions in the hemoglobin levels of patients receiving the drug compared to 
those receiving placebo. In addition, other cell lines including leucocytes and neutrophils also 
decreased while platelets increased in the majority of patients in the treatment arm compared 
to the placebo arm [50]. In general, patients with advanced disease were more likely to have 
hematologic toxic effects possibly due to reduced marrow reserves. In another study HAART 
status was not associated with anemia. Individuals who were prescribed zidovudine alone or 
HAART both experienced significant decreases in anemia prevalence. However, the 
prevalence of anemia was higher among those prescribed zidovudine with or without 
HAART [51]. Although the current use of relatively small doses of AZT in combination with 
other antiretrovirals has decreased the frequency of anemia, patients with advanced HIV 
disease on AZT at a dose of less than 500mg/day showed significantly decreased hemoglobin 
levels compared to those not taking the drug [52]. In a study documenting the potential for 
hematologic toxicity, Richman et al described the adverse reactions and AZT-related 
toxicities of a placebo trial in patients with AIDS and AIDS-related complex (ARC). 
Statistically significant reductions in hemoglobin values were observed in the AZT arm while 
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the mean corpuscular volume (MCV) increased progressively over time. White cell counts 
decreased in the AZT arm while the platelet numbers increased in many AZT recipients but 
remained the same in the placebo arm [50]. In a study of anemia in a rural HIV Ugandan 
cohort, Mugisha et al examined the prevalence at enrolment, incidence and associated risk 
factors prior to the introduction of HAART and found that the prevalence and incidence of 
anemia were higher in HIV-positive than HIV-negative individuals [53]. A more recent 
comparison of the baseline prevalence of cytopenias in treatment naïve patients at entry into a 
multicenter randomized clinical trial of HAART in diverse geographical settings showed that 
anemia was more common than neutropenia or thrombocytopenia. This study further 
demonstrated that the prevalence of hematological abnormalities in untreated individuals was 
independently related to geographical location, gender and chronic co-infections such as 
hepatitis B infection [43]. A prospective study of HIV-infected adults in Uganda showed that 
15% of patients initiated on HAART had baseline anemia and of these 5% had severe 
baseline anemia. Subjects with baseline anemia (Hemoglobin ≤9.5g/dl) experienced larger 
increases in median hemoglobin compared to the non-anemic patients and zidovudine was 
not associated with an increased risk of early severe anemia [54]. 
1.7 Cytopenias and clinical outcomes 
The use of HAART in the treatment of HIV-infected patients has led to immune 
reconstitution, decreased risk of opportunistic infections and improved survival [55]. 
However, in some patients even when viral replication is controlled and adherence is good, 
the treatment response, often measured by immunological and hematological parameters, is 
sub-optimal and results in unfavorable outcomes. 
Anemia is a non-AIDS defining HIV-related illness that has been associated with decreased 
survival [56-59]. The incidence of anemia is strongly associated with HIV disease 
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progression as measured by CD4 count [60]. Several studies have demonstrated anemia as an 
independent predictor of mortality although the mechanisms are unclear or indirect [32-34, 
37, 61, 62]. Anemia in HIV infection has an insidious onset yet it can significantly affect the 
functional status of an individual; it causes fatigue, headaches, and other symptoms that may 
range from mild to disabling disease [43]. Kowalska et al. demonstrated that starting HAART 
was associated with an increase in hemoglobin levels but more importantly that current levels 
of hemoglobin are more predictive of disease progression than the hemoglobin measured at 
the time of starting HAART [48]. If treated, anemic HIV infected individuals who recover 
from anemia have better survival rates than those who do not recover [32, 34]. 
1.8 Management of cytopenia 
Although data on the effect of anemia treatment on survival in HIV-infected individuals on 
HAART is limited, some interventions have been investigated. The use of appropriate 
interventions in the management of HIV-associated anemia is critical especially in non-
emergency situations. An observational study demonstrated that transfusion of anemic HIV-
infected individuals was associated with a three-fold excess mortality risk [51] while use of 
epoietin alfa (human erythropoietin produced in cell culture) was associated with improved 
survival in HIV [34]. A cross-sectional study of HIV-infected patients demonstrated that 
supplemental androgens had a potential role in the treatment of HIV-associated anemia and 
could be a cheaper alternative to erythropoietin therapy in addition to also treating the other 
effects of hypogonadism in these patients such as loss of lean body mass [63]. 
2 Rationale and Objectives 
The prevalence of cytopenias is determined by a number of factors including but not limited 
to immunological and virological status thus the frequency of cytopenias increases with 
disease progression. In addition, the side effects of the drugs used to treat HIV itself notably 
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zidovudine as well as treatment or prophylaxis of co-infections with cotrimoxazole for 
instance have also been noted to have a cytotoxic effect on the bone marrow with or without 
clinical consequences [50, 64]. These factors may interact with each other and ultimately 
influence the clinical outcome of the patients. The potentially life-threatening impact of 
cytopenias in HIV infected individuals warrants the understanding of the multifaceted 
causation of these abnormalities, the direct role of HIV and the extent to which HAART 
ameliorates these hematologic disorders [65]. Hemoglobin has a strong relationship with 
AIDS-defining illnesses and death. The current literature is consistent in confirming that 
anemia is a strong and independent predictor of death in HIV-infected adults [32-34, 37, 48, 
61, 62]. However, a gap still remains in characterizing the trend in hemoglobin levels during 
HIV disease [61] and particularly while patients are on therapy. The measurement of 
hemoglobin loss during HIV infection is not extensively reported yet its routine measurement 
is cheap. Studies have yielded conflicting findings on the effect of HAART (particularly 
AZT-based HAART) on hemoglobin levels; some have shown worsening while others did 
not demonstrate a significant association between AZT use and development of anemia [38, 
46, 66, 67]. Previous studies on the impact of HAART on the change in hemoglobin levels 
have focused on single measurements of hemoglobin [32, 68-70] or used selected populations 
[14, 38, 67, 70, 71] or have had a short observation time. Therefore a systematic investigation 
of hematological profiles of HIV-infected patients on HAART, in relation to 
clinical/treatment outcomes is warranted. 
2.1.1 General Objective: 
The overall objective of this study was to examine the trend in hematological parameters over 
a period of 18months and the association of these changes with the clinical outcomes in HIV 
positive adults initiating HAART.  
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2.1.2 Specific Objectives: 
1. To determine the prevalence of and factors associated with cytopenias and other 
selected hematological abnormalities that is, mean cell volume, mean corpuscular 
hemoglobin and mean corpuscular hemoglobin concentration in HIV-infected adults 
initiating HAART at baseline. 
2. To examine changes in hemoglobin status and other selected hematological 
parameters and associated factors in HIV-infected adults initiating HAART from 
baseline over 18 months. 
3. To examine the association of baseline anemia and other factors with HIV disease 
progression and with all-cause mortality, in adults initiating HAART up to 18 months 
of follow-up.  
3 Materials and Methods 
3.1 Study design, setting and population  
This study was nested in an on-going, larger clinical trial at the Infectious Diseases Institute 
(IDI) in Kampala, Uganda where 400 HIV-infected patients initiating HAART were 
randomized to either a multivitamin supplement (including vitamins B-complex, C and E) or 
a placebo, and followed for up to 18 months. Recruitment in the parent trial began in April 
2010. All patients attending the IDI clinic who were eligible for HAART at the time the trial 
was recruiting were typically initiated on any one of these combinations of drugs as a first-
line regimen: 
I. Two nucleoside reverse transcriptase inhibitors(NRTI) such as zidovudine (AZT) 
with lamivudine (3TC) and a non-nucleoside reverse transcriptase inhibitor(NNRTI) 
such as nevirapine or efavirenz 
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II. A nucleotide reverse transcriptase inhibitor such as tenofovir with either lamivudine 
or emtricitabine (FTC) and a NNRTI. 
III. A triple nucleoside drug combination such as AZT, abacavir and 3TC 
 
Brief description of the objectives, inclusion and exclusion criteria, methods and 
procedures of the parent trial 
Objectives of the parent trial 
The objective of the parent trial was to examine the efficacy of multivitamins in slowing 
disease progression among HIV-infected adults receiving HAART in Uganda using a 
randomized, double-blind, controlled study design [72]. The specific study objectives of the 
parent trial were:  
1) To determine whether oral multivitamin supplements (including vitamins B-complex, C 
and E) given daily for 18 months will: 
 a) improve immune reconstitution (indicated by CD4 cell count);  
b) improve weight gain and  
c) improve quality of life. 
2) To determine whether oral multivitamin supplements (including vitamins B-complex, C 
and E) given daily for 18 months will:  
a) reduce risk of developing a new or recurrent disease progression event including all-cause 
death;  
b) reduce the probability of changing drug therapy (indicated by switching from first- to 
second-line therapy), and  
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c) reduce the occurrence of adverse events associated with ART, indicated by peripheral 
neuropathy, severe anaemia, or diarrhea. 
Recruitment in the trial began in April 2010 and follow-up of participants was completed in 
December 2013. 
Inclusion and exclusion criteria of the parent trial 
HIV-positive adults (≥ 18 years) registered at the Infectious Diseases Institute (IDI) were 
recruited into the parent trial if they: 
i) Were HAART-naïve and eligible to start HAART or had been taking HAART for not 
more than 6 months at trial start 
ii) Had a CD4 cell count done within 8 weeks prior to trial start 
iii) Resided within a 20 kilometer radius of IDI and had no intention of migrating within 
the next 18 months 
iv) Were able to provide informed consent to participate in the trial 
Females were excluded if they were confirmed to be pregnant at trial start. Patients who were 
already attending special clinics within the IDI such as the TB clinic, the Sexual and 
Reproductive Health clinic as well as those who were already enrolled into another study 
were not recruited into the trial. However, once enrolled, subjects who needed referral to 
these clinics in the course of the trial were referred and were followed up until they 
completed trial procedures or left the trial (due to death, loss to follow up or withdrawal of 
consent to participate). 
Methods and procedures of the parent trial 
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Prior to randomization and physical contact between the study staff and any patient, pre-
eligibility screening was done by a designated study staff through conducting chart reviews 
of prospective HIV-infected patients ahead of their scheduled clinic visit to determine their 
potential eligibility for enrolment. The study staff then approached potential participants upon 
arrival at the clinic, informed them about the study and invited them for further eligibility 
confirmation and enrolment into the study. Upon obtaining written informed consent, the 
study participant was assigned a randomization number and study identification number 
which were used on all study documents. At each of the study visits, clinical and laboratory 
information was collected using standardized questionnaires and laboratory procedures. 
Blood specimens were taken from each participant at baseline and every 6 months to measure 
CD4 cell count and Complete Blood Count, malaria parasitemia and liver function. These 
specimens were analyzed by the Makerere University-John Hopkins University (MU-JHU) 
Core laboratory which is based at the study site (IDI) and is certified by the College of 
American Pathologists (CAP certificate number 7139001) and the results were provided to a 
designated study staff. Study participants were evaluated at baseline, and then at 3 months, 6 
months, 12months and at 18 months from the time of randomization into the study at which 
point they were terminated from the study. Ethical approval for the trial was obtained from 
the IDI Scientific Review Committee, the Higher Degrees, Research and Ethics Committee 
(HDREC) of the Makerere School of Public Health and the Uganda National Council of 
Science and Technology. All participants gave their written informed consent to participate in 
the trial.  
3.2 Measurements and definitions 
This was a secondary analysis of data on the Complete Blood Count (CBC, Beckman Coulter 
Act 5 Diff, Miami, Florida, USA), the CD4+ cell count (BD FACSCalibur System, Becton 
Dickson, San Jose, California, USA) and clinical information routinely collected at baseline 
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and at months 6, 12 and 18 as per parent trial protocol. Blood specimens were collected into 
EDTA vacutainers for both laboratory tests. The following laboratory parameters were 
evaluated: Hemoglobin, Mean Cell Volume (MCV), Mean Corpuscular Hemoglobin (MCH), 
Mean Corpuscular Hemoglobin Concentration (MCHC), total White Blood Cell count 
(WBC) and Platelet count. Cytopenia was defined as an abnormal hematological value of at 
least one of the 3 cell lines (white blood cells, platelets or hemoglobin) based on WHO 
guidelines where available or the reference ranges provided by the MU-JHU Core laboratory 
based at the study site. Cytopenias included anemia, leucopenia and thrombocytopenia. The 
prevalence of cytopenias was calculated as a proportion of patients with abnormal 
hematological values at baseline; the denominator being patients enrolled into the trial. 
Anemia 
Gender-specific definitions of anemia were used. Anemia was defined according to WHO 
guidelines as <12 g/dl for non-pregnant women and <13 g/dl for men. Anemia severity was 
graded as mild: 11-11.9 g/dl for women and 11-12.9 g/dl for men; moderate: 8-10.9 g/dl for 
both sexes; and < 8 g/dl as severe anemia for both sexes [73]. 
Other cytopenias 
There are no generally accepted cut-offs for other cytopenias. A study in India used a cut off 
of total white blood cells < 4000 cells/μl to define leucopenia and platelet count <150×103  
cells/μl to define thrombocytopenia in HIV-infected individuals [74]. A study conducted in 
European subjects evaluating the link between the burden of HIV-1 and hematological values 
in untreated subjects defined thrombocytopenia as <150×10
3
 platelets/µl and leucopenia as 
˂3000/µl [65]. Since most of the cut-off values from previous studies may not be comparable 
to our study population due to the different settings, we used the study site laboratory 
reference ranges (MUJHU Core laboratory) to define leucopenia and thrombocytopenia.  
Other cytopenias were thus defined as follows:  
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Leucopenia if total white blood cell count < 2.75 × 10
9 cells/litre, thrombocytopenia if platelet 
count <125 × 10
9 cells/litre for females and <156 × 10
9
  cells/litre for males; bicytopenia if a 
subject had a combination of any 2 cytopenias and pancytopenia as having all three forms of 
cytopenia simultaneously. 
Other selected hematological parameters 
We defined the cut-off values for the following hematological parameters using the study site 
laboratory reference ranges as follows:  
a) Mean Corpuscular Volume (MCV) – 73 to 99 femtolitres(fl) 
b) Mean Corpuscular Hemoglobin (MCH) – 24 to 35picograms(pg) 
c) Mean Corpuscular Hemoglobin Concentration (MCHC) – 32 to 36 g/dl 
3.3 Data management and statistical analyses 
All case report forms (CRFs) were field edited by the Study Coordinator or designee and all 
inconsistencies resolved prior to faxing of the CRFs by a designated field staff. Data entry 
and management was done using Datafax which is a Food and Drug Administration (FDA) 
auditable, secure system where paper data forms are electronically captured and transmitted 
or faxed from remote sites to a National Institutes of Health (NIH) server. The Datafax 
management team reviewed all CRFs and queried any errors, invalid and/or missing values 
through regular quality assurance (QA) and quality control (QC) reports to the study team. 
The QC report, through the patient scheduling and tracking function of datafax, also 
identified overdue visits and missing CRF pages. The field staff corrected their respective 
data queries and all changes or corrections to the data fields were re-faxed and subsequently 
tracked by user, date and time. 
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Datafax can interface with a number of programming and statistical packages such as 
ORACLE, MYSQL, Stata and SAS. All data analyses for this study were done using Stata 
version 12. 
3.3.1 Methods Objective 1:  
We assessed the participants’ baseline status using univariate analysis to describe the 
subjects’ characteristics: continuous variables were summarized using means (if normally 
distributed) or medians (in case of non-parametric distributions) and categorical variables 
were summarized using frequencies and percentages. The prevalence of the various forms of 
cytopenia is reported as a percentage of subjects with cytopenia with the denominator being 
all subjects who were enrolled in the parent trial.  
We used log-binomial regression models [75-77] to investigate the factors associated with 
cytopenias in general and with anemia, leucopenia and thrombocytopenia as individual 
outcome variables. Prevalence ratios (PR) and their 95% confidence intervals (95%CI) are 
reported. The independent factors investigated included demographic variables (e.g. sex, age, 
marital and employment status, highest level of education attained) and clinical/laboratory 
characteristics (e.g. CD4 cell count, body mass index, presence or history of oral candidiasis, 
presence or history of fever, etc.). Independent variables were considered to be significantly 
associated with the dependent variable if the respective p-value was below 0.05. 
3.3.2 Methods Objective 2:  
To examine the trend in hemoglobin status and other selected hematological parameters over 
the duration of follow-up, analyses of repeated measures taken over time were performed 
using a multi-level mixed effects linear model approach. We assessed the effect of time-
dependent covariates on the individual slopes of hemoglobin, white blood cell count, platelet 
count and other selected hematological parameters over time. The multi-level mixed-effects 
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linear regression model with repeated measures is a generalization of the standard linear 
model that caters for correlation of data within an individual over time [78-81]. This 
approach was used to describe the change in hemoglobin and in each of the other selected 
hematological parameters over time as well as the factors associated with these changes. 
Each selected hematological parameter was examined separately as the outcome variable of 
bivariate and multivariable models. Variables included in bivariate analyses were: visit 
number, sex, age, body mass index (BMI), CD4 cell count, HAART status at trial start 
(HAART naïve versus already on HAART), and duration on HAART at trial start. All 
variables available were examined in bivariate analyses and those variables with p˂0.1 or 
variables that were potentially important such as sex and age were initially included in the 
multivariable modeling but only retained in the final model if the multivariable p ˂0.05. We 
also explored potential interactions between different covariates. 
3.3.3 Methods Objective 3:  
We examined the association between baseline anemia status and HIV disease progression on 
one hand and all-cause death on the other using log-binomial regression models. We used the 
baseline hemoglobin concentration as a measure of anemia status and investigated its 
association with disease progression and death from any cause in 3 separate models. Disease 
progression was defined as the first incident opportunistic infection (OI); in the first model 
we examined the risk of death and its association with baseline anemia status; in the second 
model we examined the risk of an incident OI and its association with baseline anemia and in 
the third model all-cause death and incident OIs were considered as a composite variable with 
a binary outcome and its association with baseline anemia was examined. The covariates 
included in all the 3 models were demographic characteristics (sex, age, marital and 
employment status, highest level of education attained) and clinical/laboratory characteristics 
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(cytopenia status that is presence or absence of any form of cytopenia, mean BMI, mean CD4 
cell count, mean white blood cell count and mean platelet count). All variables were 
examined in bivariate analyses and those found to have a p-value ˂ 0.1 or with biological 
plausibility (for example age and sex) were examined in the final model. Independent 
variables were considered to be significantly associated with disease progression or death if 
the respective p-value was below 0.05. Results from these models are presented as an 
estimate of the relative risk of death and/or incident OI, that is the risk ratio (RR) and its 
corresponding 95% confidence interval. 
4 Results 
4.1 Characteristics of study participants   
Baseline hematological data were available for all 400 subjects enrolled in the parent trial of 
whom 277 (69.3%) were female. The mean age of the study population was 36 years (SD 
±9.0) and the mean BMI was 23.8 (SD ±9.2) [Table 1].  
 
Table 1: Baseline characteristics and values of the study population (N=400†) 
Characteristic Values 
Female, n (%) 277 (69.3) 
Age, mean (± S.D) years 36 (±9) 
CD4 cell count, median (IQR) per µl 142 (1-645) 
On HAART, n (%) 200 (50) 
Duration on HAART at enrollment, mean (± S.D) months 2.5 (± 1.6) 
BMI†, mean (± S.D) 23.8 (± 9.2) 
Married, n (%) 135 (33.8) 
Employed, n (%) 345 (86.3) 
Formal education (at least primary, n %)* 387 (97.0) 
Hematological values, median (IQR)   
Hemoglobin, g/dl 12.3  (4.9-17.6) 
White blood cell count (×10)⁹ per litre 3.4  (1.2-9.9) 
Platelets (×10)⁹ per litre 244  (11-616) 
Mean corpuscular volume, femtolitres (fl) 86  (58-126) 
Red cell Distribution Width (RDW), % 13.6  (9.0-25.1) 
†BMI data were missing for 3 participants due to missing weight at baseline  
*One subject had education level as “Unknown”  
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SD = Standard Deviation  
IQR = Inter Quartile Range 
The median CD4 cell count was 142 cells/μl and 50% of the subjects had initiated 
antiretroviral therapy for not more than 6 months at the time of enrolment. The mean duration 
on HAART at the time of enrolment was 2.5 months (± 1.6 SD). The median hemoglobin 
concentration was 12.3 g/dl, the median white blood cell count was 3.4 ×109 cells per litre and 
the median platelet count was 244 ×109 cells per litre. 
4.2 Prevalence of cytopenia at baseline 
A total of 260 participants (65%) had at least one form of cytopenia. Anemia was the most 
common cytopenia occurring in 192 (47.8%) of the subjects followed by leucopenia 
occurring in 96 (24.3%), thrombocytopenia in 32 (8.3%), bicytopenia in 88 (21.9%) and only 




Table 2: Distribution of cytopenias across the study population 
Variables n Any  
Cytopenia† 
Anemia† Leucopenia† Thrombocytopenia† 
All participants 400 65.0 47.8 24.3 8.3 
Demographic characteristics 
Gender      
Male 123 56.9 34.1 23.6 14.6 
Female 277 68.6 53.8 24.5 5.4 
Age 
18 to < 30 98 63.3 45.9 23.5 5.1 
30 to < 35 80 70.0 50.0 26.3 11.3 
35 to < 41 117 64.1 45.3 24.8 8.5 
≥ 41 105 63.8 50.5 22.9 8.6 
Education level 
None 12 66.7 33.3 41.7 8.3 
Minimum Primary 206 65.5 48.5 21.8 8.7 
Min. Secondary 141 66.7 50.4 25.5 8.5 
Tertiary 40 57.5 40.0 27.5 5.0 
Unknown† 1 0.0 0.0 0.0 0.0 
Employment status 
Unemployed 55 69.1 56.4 20.0 3.6 
Employed 345 64.3 46.4 24.9 9.0 
Marital status 
Not married 265 64.9 49.1 22.3 7.2 
Married 135 65.2 45.2 28.1 10.4 
Clinical characteristics 
CD4 count cells/µl      
<50 59 84.7 50.8 52.5 15.3 
50 to <200 241 62.2 49.0 20.3 6.6 
200 to < 350 88 59.1 43.2 15.9 9.1 
≥ 350 12 66.7 41.7 25.0 0.0 
BMI      
under weight 31 83.9 71.0 12.9 9.7 
normal 261 66.7 50.2 24.1 8.8 
over weight 105 54.3 34.3 25.7 6.7 
Incomplete information* 3 100.0 66.7 100.0 0.0 
HAART status at recruitment 
Not using HAART 200 68.0 47.0 26.0 12.0 
AZT-based HAART 185 66.7 60.0 6.7 0.0 
Non-AZT based HAART 15 61.6 47.6 23.8 4.9 
Presence/history of oral candidiasis 
No 305 62.0 44.9 23.3 7.5 
Yes 95 74.7 56.8 27.4 10.5 
Presence/history of fever 
No 195 63.6 44.6 26.7 8.2 
Yes 205 66.3 50.7 22.0 8.3 
†The values presented other than “n” are percentages. †One participant had education level as “Unknown”.  
*Three participants did not have baseline measurements of weight and so BMI could not be computed for 
these thus categorized as “Incomplete information” 
 
Cytopenias were most prevalent in subjects aged between 30 and 35 years (70%) and in those 
with CD4 cell counts below 50 cells/μl (84.7%).  
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4.3 Factors associated with cytopenias at baseline 
Factors found to be associated with any baseline cytopenia in multivariable regression were 




Table 3: Factors associated with the presence of any Cytopenia at baseline 
Results of uni- and multivariable log-binomial regression models 
 






cytopenia PR (95% CI) 
p 










 Female 277 
68.6 
1.21 (1.01 to 1.43) 0.035 1.32 (1.11 to 1.57) 0.002 
CD4 count cells/µl 
 
 







50 to < 200 241 
62.2 
0.73 (0.63 to 0.85) ˂0.001 0.74 (0.63 to 0.86) ˂0.001 
200 to < 350 88 
59.1 
0.70 (0.57 to 0.86) 0.001 0.73 (0.59 to 0.90) 0.003 
≥ 350 12 
66.7 









 normal 261 
66.7 
0.79 (0.67 to 0.95) 0.011 0.82 (0.69 to 0.98) 0.028 
over weight 105 
54.3 














 Yes 95 
74.7 
1.21 (1.04 to 1.40) 0.012 1.08 (0.93 to 1.26) 0.300 
HAART status at 
recruitment 
 























 30 to < 35 103 
70.0 
1.11 (0.90 to 1.36) 0.341 1.15 (0.94 to 1.40) 0.184 
35 to < 41 94 
64.1 
1.01 (0.83 to 1.24) 0.899 1.07 (0.89 to 1.30) 0.464 
≥ 41 105 
63.8 
1.01 (0.82 to 1.24) 0.936 1.11 (0.90 to 1.37) 0.328 
‡Multivariable model only includes the variables where data are shown because all others were lacking multivariable significance 
*Three participants with missing BMI were not included into log-binomial regression model because the outcome did not vary in this 
stratum. Thus n=397 for the multivariable analysis. 
The solid line demarcates those independent variables that entered into the final multivariable model (above the line) at a p-value cut off 
of 0.1 at bivariate analyses; all other independent variables (below the line) were added one at a time into the multivariable model to 





The prevalence of any baseline cytopenia in females was 30% higher than in males (adjusted 
prevalence ratio (aPR) = 1.32; 95% confidence interval [CI]: 1.11-1.57). The aPR of having 
any form of cytopenia decreased with higher CD4 count; for CD4 count category 50 to ˂ 200 
cells/μl compared to CD4 count category ˂ 50 cells/µl aPR=0.74 [95% CI: 0.63- 0.86, p˂ 
0.001], and for CD4 count category 200 to <350 compared to CD4 count category ˂ 50 
cells/µl aPR=0.73 [95% CI: 0.59-0.90, p= 0.003]. Similarly the aPR of having any form of 
baseline cytopenia decreased with higher BMI; for normal compared to underweight BMI 
aPR=0.82 [95%CI: 0.69-0.98, p=0.045] and overweight compared to underweight BMI 
aPR=0.64 [95%CI: 0.51-0.81, p<0.001].  
The factors found to have a multivariable association with baseline anemia were female sex 




Table 4: Factors associated with the presence of anemia 
Results of uni- and multivariable log-binomial regression models 
Covariate 
  
Univariable  Multivariable‡  
 
N=400  PR (95% CI)  p value PR (95% CI) p value 
 
      n 
% with 
anemia     
Sex 
Male 123 34.1 1 
 
1 
 Female 277 53.8 1.58 (1.20 to 2.06) 0.001 1.76 (1.33 to 2.31) <0.001 
BMI 




normal 261 50.2 0.71 (0.55 to 0.91) 0.033 0.75 (0.57 to 0.97) 0.031 
over weight 105 34.3 0.48 (0.34 to 0.68) 0.001 0.46 (0.32 to 0.66) <0.001 
Incomplete 
information* 3 66.7 0.94 (0.41 to 2.16) 0.883 1.53 (0.64 to 3.65) 0.342 
Presence/history of oral candidiasis 
    No                          305       44.6      1                                                    1 
    Yes                         95        56.8       1.27 (1.02 to 1.57)         0.032          1.16 (0.94 to1.44)         0.169 
CD4 count cells/µl 




50 to <200 241 49.0 0.96 (0.73 to 1.28) 0.793 0.96 (0.73 to 1.27) 0.780 
200 to <350 88 43.2 0.85 (0.60 to 1.20) 0.356 0.92 (0.66 to 1.29) 0.623 
≥ 350 12 41.7 0.82 (0.40 to 1.67) 0.585 0.71 (0.37 to 1.37) 0.311 
Age, years 




30 to < 35 80 50.0 1.09 (0.80 to 1.48) 0.587 1.19 (0.90 to 1.60) 0.225 
35 to < 41 117 45.3 0.99 (0.74 to 1.32) 0.928 1.07 (0.81 to 1.41) 0.627 
≥ 41 105 50.5 1.10 (0.83 to 1.46) 0.517 1.26 (0.96 to 1.67) 0.098 
HAART status at recruitment 




AZT-based HAART 185 47.6 1.01 (0.82 to 1.25) 0.911 1.07 (0.87 to 1.31) 0.519 
Non-AZT based 
HAART 15 60.0 1.28 (0.82 to 1.98) 0.275 1.09 (0.71 to 1.66) 0.705 
Presence/history of fever 




Yes 205 50.7 1.14 (0.92 to 1.89) 0.221 1.12 (0.91 to 1.37) 0.280 
 ‡Multivariable model only includes the variables where data are shown because all others were lacking 
multivariable significance. 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.1 at bivariate analyses; all other independent variables (below the line) were 





The adjusted prevalence of baseline anemia among females was 70% higher than that in 
males; aPR= 1.76 [95% CI: 1.33-2.31, p˂0.001]. Anemia prevalence decreased with higher 
BMI; aPR of those in the normal BMI category compared to the underweight category was 
0.75 [95% CI: 0.57-0.97, p=0.031] and for those in the overweight BMI category compared 
to the underweight category, aPR=0.46 [95% CI: 0.32-0.66, p˂ 0.001]. Similarly the 
prevalence of baseline anemia decreased with higher CD4 cell count category although these 
differences were not statistically significant: those in CD4 count category 50 to ˂200 cells/µl 
compared to CD4 count category ˂ 50 cells/µl, unadjusted PR (uPR) =0.96, [95% CI: 0.73-
1.28] and for those in CD4 count category 200 to ˂350, uPR= 0.85 [95% CI: 0.60-1.20]. The 
prevalence of baseline anemia in those with current or a previous history of oral candidiasis 
was 27% higher than in those with no prior history [uPR=1.27; 95% CI: 1.02-1.57, p=0.032]. 
Factors associated with the presence of baseline thrombocytopenia in multivariable 
regression were sex and whether a subject was on HAART at the start of the trial on not 




Table 5: Factors associated with the presence of thrombocytopenia 
Results of uni- and multivariable log-binomial regression 
Covariate   Univariable   Multivariable   
 N=400  PR (95%CI) 
P 




(%)     
Sex 
      Male 123 14.6 1 
 
1 
 Female 277 5.4 0.37 (0.19to 0.71) 0.003 0.38 (0.20 to 0.72) 0.003 
HAART status at 
recruitment § 
     Not on 
HAART 200 12.0 1 
 
1 
 On HAART 200 4.5 0.375 (0.18to 0.79) 0.009 0.38 (0.18 to 0.81) 0.012 
CD4 count 
cells/µl 
      <50 59 15.3 1 
 
1 
 50 to < 200 241 6.6 0.44(0.20 to 0.94) 0.033 0.60 (0.28to 1.29) 0.191 
≥ 200 ** 100 8.0 0.52(0.21 to 1.29) 0.158 0.89 (0.36 to 2.21) 0.807 
BMI 
      under weight 31 9.7 1 
 
1 
 normal 261 8.8 0.91(0.29 to 2.86) 0.873 0.98(0.33 to 2.94) 0.970 
over weight 105 6.7 0.69(0.19 to 2.51) 0.572 0.99(0.28 to 3.49) 0.983 
Incomplete 
information* 3 0.0 - - - 
 Age, years 
      18 to < 30 98 5.1 1 
 
1 
 30 to < 35 80 11.3 2.21(0.77 to 6.32) 0.141 1.75(0.61 to 5.01) 0.295 
35 to < 41 117 8.5 1.68(0.59 to 4.73) 0.328 1.41(0.50 to 3.97) 0.512 




      No 305 7.5 1 
 
1 
 Yes 95 10.5 1.40(0.69 to 2.83) 0.354 1.19(0.58 to 2.46) 0.630 
Presence/history 
of fever 
      No 195 8.2 1 
 
1 
 Yes 205 8.3 1.01(0.53 to 1.94) 0.975 1.03(0.54 to1.93) 0.938 
‡ Multivariable model only includes variables where data are shown because all others lacked significance 
* Three participants with missing BMI could not be included into log-binomial regression since the outcome 
did not vary in this group 
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**Categories “200 to 350” and “≥350” were combined for this analysis because none of the participants with 
CD4 counts ≥350 had thrombocytopenia 
§All subjects on HAART were categorized into one group for this analysis because none of the 15 subjects on 
AZT-based HAART had thrombocytopenia 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.1 at bivariate analyses; all other independent variables (below the line) were 
added one at a time into the multivariable model to obtain their respective multivariable PR 
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Females had a 62% lower prevalence of baseline thrombocytopenia compared to males 
aPR=0.38; [95% CI: 0.20-0.72, p=0.003]. The prevalence of having thrombocytopenia among 
those on HAART compared to those who were not yet on HAART at the start of the trial was 
62% lower aPR=0.38; [95% CI: 0.18- 0.81, p=0.012]. Patients in the CD4 count category 50 
to ˂200 cells/µl had a 40% lower prevalence of baseline thrombocytopenia compared to those 
in CD4 count category ˂50 cells/µl (reference); aPR=0.60 [95% CI: 0.28 to 1.29, p=0.191] 
while those with CD4 count ≥ 200 cells/µl had a 10% lower prevalence of baseline 
thrombocytopenia compared to the reference group aPR=0.89 [95%CI: 0.36 to 2.21, 
p=0.807]. 
The only factor associated with the presence of baseline leucopenia in multivariable 




Table 6: Factors associated with presence of baseline leucopenia 
 Results of uni- and multivariable log-binomial regression 
models 
Covariate  Univariable  
(n=400) 
            
Multivariable‡  




leucopenic PR (95% CI)  p value PR (95% CI) p value 
CD4 count cells/µl 
 
 







50 to <200 241 
20.3 
0.39 (0.27 to 0.55) <0.001 0.41 (0.29 to 0.59) ˂0.001 
200 to <350 88 
15.9 
0.30 (0.18 to 0.52) <0.001 0.32 (0.19 to 0.55) ˂0.001 
≥ 350 12 
25.0 
0.48 (0.17 to 1.31) 0.149 0.64 (0.24 to 1.72) 0.377 
HAART status at recruitment 
 
 
    






AZT-based HAART 185 
23.8 
0.26 (0.04 to 1.73) 0.162 0.32 (0.05 to 2.22) 0.25 
Non-AZT based HAART 15 
6.7 




    








1.87 (0.73 to 4.79) 0.191 2.00 (0.80 to 5.01) 0.137 
over weight 105 
25.7 
1.99 (0.75 to 5.26) 0.164 2.06 (0.80 to 5.30) 0.131 
Incomplete information* 3 
100 

















    






30 to < 35 80 
26.3 
1.12 (0.67 to 1.87) 0.669 1.01 (0.63 to 1.63) 0.971 
35 to < 41 117 
24.8 
1.06 (0.66 to 1.70) 0.822 1.20 (0.77 to 1.88) 0.419 
≥ 41 105 
22.9 
0.97 (0.59 to 1.61) 0.918 1.04 (0.65 to 1.67) 0.856 













1.18 (0.80 to 1.73) 0.411 0.90 (0.62 to 1.31) 0.587 
Presence/history of fever 
 
 









0.82 (0.58 to 1.17) 0.272 0.77 (0.55 to 1.06) 0.106 
* Three participants with missing BMI were not included into log-binomial regression model because the outcome did not vary in this 
stratum. Thus n=397 for the multivariable analysis. 
The solid line demarcates those independent variables that entered into the final multivariable model (above the line) at a p-value cut off 
of 0.1 at bivariate analyses; all other independent variables (below the line) were added one at a time into the multivariable model to 




The prevalence of baseline leucopenia in those with CD4 count of 50 to <200 cells/μl was 60 
% lower compared to those with CD4 count <50 cells/μl; aPR=0.39 [95%CI: 0.27-0.55, 
p<0.001]. The prevalence of baseline leucopenia in those with CD4 count of 200 to <350 
cells/μl was 70% lower than those with CD4 count <50 cells/μl; aPR= 0.307 [95%CI: 0.18-
0.52, p <0.001]. Interestingly, the prevalence of baseline leucopenia in those with CD4 counts 
≥ 350 cells/µl was only 50% lower than in the reference group although this difference was 
not statistically significant. 
4.4 Trends in hematological parameters following initiation of HAART  
Of the 400 subjects enrolled in the trial, a total of 1517 laboratory observations were 
available for the analyses of the trends in hematological parameters. The reasons for the 
missing laboratory observations (n=83) included specimen not being collected at the 
consequent visit, death occurring before completion of all study procedures, clotted 
specimen, withdrawal from the trial and loss to follow-up. 
The general trend in hemoglobin, selected Red Blood Cell (RBC) indices and other cell lines 
We assessed trends over time in hemoglobin concentration and in the following RBC indices: 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean 
corpuscular hemoglobin concentration (MCHC) from baseline through the follow-up time 
points. 
The mean hemoglobin concentration of all 400 subjects at enrolment was 12.3 g/dl and 
increased over time reaching its maximum of 13.3 g/dl after 18 months of follow-up (Table 
7). Of the 191 subjects who were anemic at baseline, 57.6% had mild anemia, 38.2% had 
moderate anemia and 4.2% had severe anemia. Furthermore, the majority of subjects (82%) 





Table 7: Hemoglobin Status and Other RBC Indices of HIV-Infected Adults while on HAART 
                                                                Time point in months (N) 
Parameter 0 (400) 6 (380) 12 (371) 18 (366) 
Mean hemoglobin (g/dl)  
   All subjects 12.3 12.9 13.2 13.3 
Females  11.7 12.3 12.5 12.6 
Males  13.6 14.4 14.8 14.8 
Severity of anemia, n (%)  
   All anemic 191 (47.8) 110 (28.9) 90 (24.3) 82 (22.3) 
Mild 110 (27.5) 73 (19.2) 63 (17.0) 60 (16.4) 
Moderate 73 (18.3) 32 (8.4) 26 (7.0) 19 (5.2) 
Severe 8 (2.0) 5 (1.3) 1(0.3) 3 (0.8) 
RBC Size, n (%)  
   Normocytic 326 (82) 126(33) 121 (33) 119 (33) 
Microcytic 57 (14) 246 (65) 242 (65) 239 (65) 
Macrocytic 17 (4) 8 (2) 8 (2) 8 (2) 
Other RBC Indices  
   Mean MCV (fl) 87.5 101.7 102.8 102.9 
Mean MCH (pg) 29.5 34.3 34.6 34.6 
Mean MCHC (%) 33.6 33.7 33.6 33.5 
 
The baseline mean hemoglobin concentration was higher for males (13.6 g/dl) than for 
females (11.7 g/dl) and this difference by sex remained over the duration of follow-up. The 
mean MCV at baseline was within the normal range (87.5 fl) but gradually increased over 
time to macrocytosis (mean MCV 102.9 fl) at 18 months. The mean MCH and the mean 
MCHC were within normal ranges from baseline throughout the follow-up duration. 
 
Figures 1-3 show the trends in (1) mean hemoglobin concentration (2), mean WBC count and 




Figure 1: Trend in mean hemoglobin concentration over time. Data are means; bars are 
standard deviations 
 
Figure 2: Trend in mean white blood cell count over time. Data are means; bars are standard 
deviations 
 






Change in hemoglobin level over time 
There was a statistically significant increase in hemoglobin level with each follow-up visit 
and hemoglobin levels were significantly higher at each visit compared to the baseline visit 
(Table 8).  
Table 8: Change in hemoglobin in HIV-infected HAART-treated adults over 18 months 
Results of bivariate and multivariable multilevel mixed effects linear regression models with 
Patient ID as random effect 













Visit number (Months)       
0 400 12.3 0 - 0 - 
6 380 12.9 0.64 0.51 to 0.78ᵃ 0.59 0.34 to 0.83ᵃ 
12 371 13.2 0.86 0.72 to 1.00ᵃ 0.93 0.68 to 1.18ᵃ 
18 366 13.3 0.95 0.81 to 1.09ᵃ 0.90 0.65 to 1.15ᵃ 
Sex       
Male 123 13.6 0 - 0 - 
Female 277 11.7 -2.08 -2.36 to -1.80ᵃ -2.03 -2.34 to -1.71ᵃ 
BMI (kg/m²)       
Underweight 22 11.3 0 - 0 - 
Normal 264 12.2 1.19 0.77 to 1.62ᵃ 0.86 0.48 to 1.25ᵃ 
Overweight 114 12.5 1.81 1.35 to 2.26ᵃ 1.39 0.97 to 1.80ᵃ 
CD4 count (cells/µl)       
<50 59 12.1 0 - 0 - 
50 to < 200 241 12.2 0.94 0.66 to 1.22ᵃ 0.51 0.24 to 0.79 
200 to < 350 88 12.6 1.43 1.14 to 1.73ᵃ 0.67 0.37 to 0.97ᵃ 
≥ 350 12 11.9 1.74 1.41 to 2.06ᵃ 0.81 0.47 to 1.15ᵃ 
Age (per year) 400 12.9 0.02 0.002 to 0.04ᵇ -0.001 -0.02 to 0.01
c
 
ART status at trial start       
ART naïve 200 12.3 0 - 0  
On ART 200 12.2 0.12 -0.20 to 0.45ᶜ -0.11 -0.36 to 0.14
c
 
Duration on ART at trial start 
(Months) 
    
˂ 1 month 201 12.8 0 - 0  
1-2 months 117 12.9 0.05 -0.32 to 0.43ᶜ -0.18 -0.46 to 0.11
c
 
≥3 months 82 13.1 0.26 -0.16 to 0.68ᶜ 0.02  -0.30 to 0.35
c
 
a=p˂0.001 b=0.001≤p≤0.05   c=p˃0.05 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.05; all other independent variables (below the line) were added one at a time 




Hemoglobin levels significantly increased with higher body mass index (BMI), CD4 cell 
count category and age. However, hemoglobin levels for all visits compared to the baseline 
visit were significantly lower in females than in males by 2.03 g/dl [95% CI: -2.34 to -1.71] 
after controlling for visit number, BMI, CD4 cell count category and age. In the interaction 
analyses (data not shown in table) hemoglobin levels were lower by 0.45g/dl [95% CI: -0.74 
to -0.16] and by 0.33 g/dl [95%CI:-0.62 to -0.04]  in females than in males at 12 months and 
at 18 months respectively compared to the baseline visit. 
Trend in the prevalence of anemia 
The prevalence of anemia decreased from 47.8% at baseline to 28.9%, 24.3% and 22.3% at 
months 6, 12 and 18 respectively. Figure 2 shows the trend in the prevalence of anemia and 
its severity over time.  
 
Figure 4: The trend in prevalence and severity of anemia over time 
The prevalence of each grade of anemia that is mild, moderate and severe anemia reduced 
significantly over time (Table 7). The greatest reduction in anemia prevalence from baseline 





Change in Mean Cell Volume (MCV) over time 
There was an increase in MCV with each follow-up visit compared to the baseline when 
adjusted for CD4 count, age and duration on ART at trial start (Table 9). However increments 




Table 9: Change in Mean Cell Volume (MCV) of HIV-infected HAART-treated adults 
Results of bivariate and multivariable multilevel mixed effects linear regression models with 
Patient ID as random effect 















      
0 400 87.5 0 - 0 - 
6 380 101.7 14.1 13.2 to 14.9ᵃ 13.2 12.3 to 14.1ᵃ 
12 371 102.8 15.0 14.1 to 15.8ᵃ 13.9 13.0 to 14.8ᵃ 
18 366 102.9 15.1 14.2 to 15.9ᵃ 13.9 12.9 to 14.8ᵃ 
CD4 count (cells/µl)       
<50 59 84.4 0 - 0 - 
50 to < 200 241 87.2 10.6 8.3 to 12.8ᵃ 3.3 1.6 to 5.0ᵃ 
200 to < 350 88 90.0 18.1 15.7 to 20.5ᵃ 4.6 2.7 to 6.6ᵃ 
≥ 350 12 89.7 22.1 19.5 to 24.7ᵃ 5.3 3.1 to 7.5ᵃ 
Age (per year) 400 98.5 0.17 0.05 to 0.3ᵇ 0.2 0.02 to 0.3ᵇ 
Duration on ART at 
trial start (months) 
      
˂1 month 201 97.6 0 - 0 - 
1-2 months 117 97.7 0.5 -2.1 to 3.1ᶜ -0.2 -2.8 to 2.3c 
≥3 months 82 101.8 4.4 1.5 to 7.4b 3.8 0.9 to 6.7b 
BMI (kg/m²)       
Underweight 22 85.6 0 - 0 - 
Normal 264 87.3 5.0 1.2 to 8.7ᵇ -0.2 -2.7 to 2.3c 
Overweight 114 88.2 9.7 5.8 to 13.7ᵃ -0.6 -3.3 to 2.1c 
ART Status  
at trial start 
      
ART naïve 200 83.2 0 - 0 - 
On ART 200 91.7 2.1 -0.2 to 4.4ᶜ 3.2 -18.7 to 25.1c 
Sex       
Male 123 88.8 0 - 0 - 
Female 277 86.9 -0.6 -3.1 to 1.8ᶜ -0.4 -2.8 to 2.0c 
a=p˂0.001 b= 0.001≤p≤0.05   c=p≥0.05  
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.05; all other independent variables (below the line) were added one at a time 
into the final model to obtain their respective multivariate coefficient 
 
Furthermore, in both models MCV increased with higher CD4 cell count category. This 
difference was statistically significant at 6 months after enrolment but remained significant at 
consequent visits only for those in the CD4 cell count category ≥350 cells/µl in the 
interaction analysis (data not shown).  
 42 
 
For every one year increase in age, the MCV went up by 0.15 fl when adjusted for the visit 
number, CD4 cell count and duration on ART at trial start [95% CI: 0.02 to 0.3; p=0.019]. 
Change in mean corpuscular hemoglobin over time 
The mean corpuscular hemoglobin (MCH) was significantly higher at each follow-up visit 
when compared to baseline, both in the bivariate and in the multivariable models (Table 10). 




Table 10: Change in Mean Corpuscular Hemoglobin (MCH) of HIV-infected HAART-treated adults 
Results of bivariate and multivariable multilevel mixed effects linear regression models 
with Patient ID as random effect 














      
0 400 29.5 0 - 0 - 
6 380 34.3 4.8 4.5 to 5.1ᵃ 4.5 4.1 to 4.8ᵃ 
12 371 34.6 5.0 4.7 to 5.3ᵃ 4.6 4.3 to 5.0ᵃ 
18 366 34.6 5.0 4.7 to 5.3ᵃ 4.6 4.2 to 5.0ᵃ 
CD4 count 
(cells/µl) 
      
<50 59 28.6 0 - 0 - 
50 to < 200 241 29.4 3.7 2.9 to 4.5ᵃ 1.3 0.6 to 1.9ᵃ 
200 to < 350 88 30.3 6.2 5.4 to7.1ᵃ 1.7 1.0 to 2.4ᵃ 
≥ 350 12 30.4 7.6 6.6 to 8.5ᵃ 1.9 1.1 to 2.7ᵃ 
Age (per year) 400 33.2 0.06 0.01to 0.1ᵇ 0.05 0.004 to 
0.1ᵇ 
Duration on ART 
at trial start 
(Months) 
      
˂1 month 201 32.9 0 - 0  
1-2 months 117 32.9 0.1 -0.9 to 1.1ᶜ -0.1 -1.1 to 0.8c 
≥3 months 82 34.4 1.6 0.4 to 2.7b 1.3 0.2 to 2.4b 
BMI (kg/m²)       
Underweight 22 28.8 0 - 0 - 
Normal 264 29.5 1.8 0.4 to 3.1ᵇ -0.02 -1.0 to 0.9c 
Overweight 114 29.7 3.5 2.1 to 4.9ᵃ -0.003 -1.0 to 1.0c 
ART Status at 
trial start 
      
ART naïve 200 28.1 0 - 0 - 
On ART 200 30.9 0.7 -0.1 to 1.5ᶜ 0.5 -7.7 to 8.8c 
Sex       
Male 123 30.1 0 - 0 - 
Female 277 29.3 -0.3 -1.3 to 0.6ᶜ -0.3 -1.2 to 0.6c 
       
a=p˂0.001 b= 0.001≤p≤0.05 c=p˃0.05 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.05; all other independent variables (below the line) were added one at a time 
into the final model to obtain their respective multivariate coefficient 
 
The MCH increased with higher CD4 cell count category and this difference remained 
significant after adjusting for visit number, age and duration on ART at enrollment. In the 
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interaction analyses,(data not shown) the increase in MCH with higher CD4 count category 
remained statistically significant up to 18 months for those in the highest CD4 count category 
that is CD4 count ≥ 350 cells/µl.  
Change in mean corpuscular hemoglobin concentration (MCHC) over time 
Overall the mean corpuscular hemoglobin concentration (MCHC) did not change much over 
the whole duration of follow-up and none of the follow-up visits was significantly different 
from baseline. In the bivariate analyses, none of the examined variables showed a significant 





Table 11: Change in Mean Corpuscular Hemoglobin Concentration (MCHC) in HIV-infected Adults 
Results of bivariate multi-level mixed effects linear regression models 






Visit number (Months) 
0 400 33.6 0  
6 380 33.7 0.1 -0.1 to 0.3ᶜ 
12 371 33.6 -0.04 -0.2 to 0.2ᶜ 
18 366 33.5 -0.1 -0.3 to 0.1ᶜ 
CD4 count (cells/µl) 
<50 59 33.8 0  
50 to < 200 241 33.6 0.1 -0.3 to 0.4ᶜ 
200 to < 350 88 33.6 -0.03 -0.4 to 0.3ᶜ 
≥ 350 12 33.8 -0.1 -0.5 to 0.2ᶜ 
Age (per year) 400 33.6 -0.002 -0.01 to 0.01ᶜ 
ART Status at trial start 
ART naïve 200 33.6 0  
On ART 200 33.6 -0.02 -0.2 to 0.2ᶜ 
Sex     
Male 123 33.7 0  
Female 277 33.6 -0.1 -0.3 to 0.1ᶜ 
Duration on ART at trial start  
(Months) 
˂1 month 201 33.6 0  
1-2 months 117 33.5 -0.1 -0.3 to 0.2ᶜ 
≥3 months 82 33.7 0.1 -0.2 to 0.3ᶜ 
BMI (kg/m²) 
Underweight 22 33.6 0  
Normal 264 33.6 0.1 -0.4 to 0.5ᶜ 
Overweight 114 33.6 0.01 -0.5 to 0.5ᶜ 
a=p˂0.001 b= 0.001≤p≤0.05 c=p˃0.05 
 
Change in White Blood Cell (WBC) count over time 
White blood cell (WBC) counts increased with consecutive follow-up visits compared to the 
baseline in the unadjusted model. However, after adjusting for sex and CD4 count category, 
the WBC counts decreased over time compared to the baseline and this difference was 
statistically significant (Table 12).  
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Table 12: Change in white blood cell counts of HIV-infected HAART-treated adults over 18 months 
Results of bivariate and multivariable multilevel mixed effects linear regression models with 
Patient ID as random effect 


















      
0 400 3.60 0 - 0 - 
6 380 3.68 0.08 -0.05 to 0.20ᶜ -0.16 -0.29 to -0.03ᵇ 
12 371 3.71 0.13 0.004 to 0.25ᵇ -0.16 -0.29 to -0.03ᵇ 
18 366 3.72 0.14 0.02 to 0.26ᵇ -0.21 -0.34 to -0.01b 
Sex       
Male 123 3.89 0 - 0 - 
Female 277 3.46 -0.24 -0.45 to -0.03ᵇ -0.31 -0.51 to -0.11b 
CD4 count 
(cells/µl) 
      
<50 59 2.98 0 - 0 - 
50 to < 200 241 3.59 0.69 0.46 to 0.92ᵃ 0.77 0.54 to 1.01ᵃ 
200 to < 350 88 3.99 0.87 0.63 to 1.10ᵃ 1.03 0.78 to 1.29ᵃ 
≥ 350 12 3.77 1.29 1.03 to 1.55ᵃ 1.52 1.22 to 1.81ᵃ 
ART Status at 
trial start 
      
ART naïve 200 3.45 0 - 0 - 
On ART 200 3.74 0.17 -0.02 to 0.37ᶜ 0.12 -0.07 to 0.31c 
Age (per year) 400 3.68 -0.002 -0.01 to 0.01ᶜ -0.01 -0.02 to 0.005c 
BMI (kg /m²)       
Underweight 22 3.74 0 - 0 - 
Normal 264 3.58 -0.24 -0.58 to 0.11ᶜ -0.31 -0.64 to 0.02c 
Overweight 114 3.61 0.004 -0.35 to 0.36ᶜ -0.14 -0.49 to 0.21c 
Duration on ART  
at trial start (Months) 
    
˂1 month 201 3.6 0 - 0 - 
1-2 months 117 3.7 0.1 -0.1 to 0.3ᶜ 0.07 -0.14 to 0.29c 
≥3 months 82 3.8 0.3 0.002 to 0.5b 0.18 -0.06 to 0.43c 
a=p˂0.001 b= 0.001≤p≤0.05 c=p˃0.05 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.05; all other independent variables (below the line) were added one at a time 




WBC counts were lower in females compared to males by 0.31×10
3
cells/µl [95% CI: -0.51 to 
-0.11, p=0.003] when controlling for visit number and CD4 cell count category. However, in 
the interaction analysis WBC counts were higher in females than males by 0.49×10
3
cell/µl 
[95% CI: 0.23 to 0.75] 18 months after enrolment (data not shown). 
Change in platelet count over time 
Overall the platelet counts increased from baseline throughout the duration of follow-up 
after adjusting for sex, CD4 cell count category and BMI. The only decrease observed was 
at 18 months in the adjusted model however, the differences observed in this model were not 




Table 13: Change in platelet counts of HIV-infected HAART-treated adults over 18 months 
Results of bivariate and multivariable multilevel mixed effects linear regression models with  
















Visit number  
(Months) 
0 400 252 0 - 0 - 
6 380 264 11.9 4.5 to 19.3b 6.1 -1.8  to 14.1ᶜ 
12 371 261 10.0 2.6 to 17.5b 3.3 -5.1 to 11.6c 
18 366 257 6.7 -0.8 to 14.2ᶜ -1.1 -9.8 to 7.7c 
Sex       
Male 123 236 0 - 0 - 
Female 277 259 37.2 22.9 to 51.6ᵃ 36.3 21.7 to 50.9a 
CD4 cell count  
(cells/µl) 
< 50 59 215 0 - 0 - 
50 to < 200 241 254 29.6 15.1 to 44.2ᵃ 28.8 13.9 to 43.7ᵃ 
200 to < 350 88 264 37.0 21.9 to 52.1ᵃ 36.4 20.0 to 52.9ᵃ 
≥ 350 12 296 44.1 27.4 to 60.9ᵃ 43.0 24.2 to 61.9ᵃ 
BMI (kg/m²)       
Underweight 22 244 0 - 0 - 
Normal 264 250 -25.0 -46.5 to 3.5ᵇ -29.0 -50.2 to -7.8b 
Overweight 114 257 -17.5 -40.2 to 5.2ᶜ -30.9 -53.6 to -8.1b 
ART status  
at enrolment 
ART naïve 200 225 0 - 0 - 
On ART 200 279 18.7 5.1 to 32.2b 20.2 7.1 to 33.4ᵇ 
Age (per year) 400 259 -0.4 -1.2 to 0.3ᶜ -0.2 -1.0 to 0.5c 
ART duration  
at trial start (Months) 
˂1 month 201 250 0 - 0  
1-2 months 117 272 21.6 5.9 to 37.4ᵇ 23.8 8.6 to 39.0b 
≥3 months 82 259 12.0 -5.7 to 29.8c 12.8 -4.4 to 30.0c 
a=p˂0.001 b= 0.001≤p≤0.05 c=p˃0.05 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.05; all other independent variables (below the line) were added one at a time 
into the final model to obtain their respective multivariate coefficient 
 
Platelet counts for all visits were higher in females compared to males by 36.3×10
3
cells/µl 
[95% CI: 21.7 to 50.9, p˂0.001] after controlling for CD4 count, visit number and BMI. 
Similarly platelet counts increased with higher CD4 cell count category and in those who had 
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already been on HAART compared to those who were HAART-naïve at the time of 
enrolment [Coeff: 20.2; 95% CI: 7.1 to 33.4, p =0.003].  
4.5 Association of baseline anemia and other factors with HIV disease 
progression and/or death in adults initiating HAART  
HIV disease progression was defined by the first incident OI in a subject. A total of 17 deaths 
and 17 incident OIs occurred during the follow-up period. The causes of death were 
adjudicated based on available clinical, laboratory and vital status information. Tuberculosis 
(both suspected and confirmed) was the most common primary cause of death (n=5) followed 
by malignancy (n=2) including Kaposi’s sarcoma and cervical cancer and cryptococcal 
meningitis (n=2). Other causes of death included pregnancy-related complications (n=1), 
toxoplasmosis (n=1) and deep vein thrombosis (n=1). The cause of death was unknown in 5 
patients.  
Association of baseline anemia and other factors with all-cause death 
The multivariable factors found to be associated with death from any cause were the presence 




Table 14: Association of baseline anemia status and other factors with all-cause death in HIV-Infected Adults 
Initiating HAART 
 
  Bivariate Multivariate 
Covariate n % died Risk Ratio (95% CI) Risk Ratio (95% CI) 
Baseline Anemia      
Absent  209 1.43 1 1 
Present  191 7.85 5.47(1.61 to 18.6)b 5.38 (1.65 to 17.5)b 
Mean CD4 count (cells/µl)   0.99 (0.98 to 0.99)ᵃ 0.99 (0.98 to 0.99)ᵃ 
Age (per year)   1.01 (0.95 to 1.06)d 1.00 (0.96 to 1.06)d 
Sex      
Male  123 3.3 1 1 
Female  277 5.1 1.55(0.52 to 4.63)d 1.51 (0.54 to 4.21)d 
Cytopenia status      
Absent  140 1.4 1 1 
Present  260 6.2 4.31 (1.00 to 18.50)ᵇ 0.65 (0.06 to 7.45)d 
Marital Status    
  Not Married  265 4.2 1 1 
Married  135 5.2 1.25 (0.49 to 3.15)d 1.35 (0.60 to 3.02)d 
Employment Status    
  Not Employed  55 1.8 1 1 
Employed  345 4.9 2.71 (0.37 to 20.0)d 2.04 (0.32 to 13.2)d 
Educational Level    
  None  13 7.7 1 1 
Primary  206 5.3 0.69 (1.00 to 4.98)d 0.27 (0.04 to 1.94)d 
Secondary  141 2.8 0.37 (0.04 to 3.07)d 0.14 (0.02 to 1.06)c 
Tertiary  40 5.0 0.65 (0.06 to 6.62)d 0.31 (0.03 to 2.88)d 
Mean BMI   0.97 (0.84 to 1.13)d 1.01 (0.88 to 1.16)d 
Mean WBC   1.05 (0.57 to 1.96)d 1.25 (0.81 to 1.93)d 
Mean PLT   1.00 (0.99 to 1.01)d 1.00 (0.99 to 1.01)d 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.1 at bivariate analyses; all other independent variables (below the line) were 
added one at a time into the multivariable model to obtain their respective multivariate RR 
The mean values shown in the table are the mean of each specified independent variable per participant over 
the follow-up duration of 18 months. 
a=p≤0.001 b= 0.001˂p ≤0.05  c=0.05˂p≤0.1 d=p>0.1 
 
There was a five-fold increased risk of death among those with anemia at baseline compared 
to those without baseline anemia after controlling for the mean CD4 cell count over the 
follow-up duration [adjusted RR (aRR) = 5.38; 95% CI: 1.65 to 17.5, p=0.005]. An increase 
in the mean CD4 cell count was associated with a decrease in the risk of death after adjusting 
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for baseline anemia status [aRR= 0.99; 95% CI: 0.98 to 0.99, p˂ 0.001]. Increase in age per 
year was not associated with risk of death after controlling for baseline anemia status and the 
mean CD4 cell count over the duration of follow-up [aRR 1.00 95% CI: 0.96 to 1.06]. 
Females had a 50% increased risk of death compared to males although this association was 
not significant [aRR= 1.51; 95% CI: 0.54 to 4.21]. Having any form of cytopenia compared 
to not having any form of cytopenia at baseline was associated with a four-fold increased risk 
of death [crude RR= 4.31; 95% CI: 1.01 to 18.50, p= 0.05]. However, after adjusting for 
baseline anemia status and the mean CD4 cell count, there was no association between the 
presence of any cytopenia and the risk of death.  
Association of baseline anemia and other factors with incident OIs 
The presence of baseline anemia was associated with a 16% increased risk of incident OIs 
however this association was not statistically significant after adjusting for the mean CD4 cell 
count, age and the mean body mass index over the duration of follow-up [aRR= 1.16; 95% 




Table 15: Association of baseline anemia status and other factors with incident OIs in HIV-Infected Adults 
Initiating HAART 
 
  Bivariate Multivariate 
Covariate n % with OI Risk Ratio (95% CI) Risk Ratio (95% CI) 
Baseline Anemia      
Absent   209 3.8 1 1 
Present  191 4.7 1.23 (0.48 to 3.13)d 1.16 (0.47 to 2.84)d 
Mean CD4 count (cells/µl)   0.99 (0.99 to 1.00)b 0.99 (0.99 to 1.00)b 
Age (per year)   0.95 (0.91 to 1.00)c 0.97 (0.92 to 1.01)d 
Mean BMI   0.87 (0.74 to 1.01)c 0.89 (0.75 to 1.05)d 
Mean WBC   1.36 (0.90 to 2.06)d 1.42 (0.97 to 2.07)c 
Sex      
Male  123 6.5 1 1 
Female  277 3.3 0.50 (0.20 to 1.27)d 0.62 (0.22 to 1.72)d 
Mean PLT   1.00 (1.00 to 1.01)d 1.00 (1.00 to 1.01)d 
Cytopenia status      
Absent  140 4.3 1 1 
Present  260 4.2 0.99 (0.37 to 2.62)d 0.52 (0.12 to 2.33)d 
Marital Status    
  Not Married  265 4.5 1 1 
Married  135 3.7 0.82 (0.29 to 2.28)d 1.01 (0.35 to 3.00)d 
Employment Status    
  Not Employed  55 3.6 1 1 
Employed  345 4.4 1.20 (0.28 to 5.09)d 1.34 (0.29 to 6.09)d 
Educational Level    
  Primary  219 3.7 1 1 
Secondary  141 5.0 1.36 (0.50 to 3.67)d 1.41 (0.52 to 3.78)d 
Tertiary  40 5.0 1.37 (0.30 to 6.22)d 1.33 (0.29 to 6.03)d 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.1 at bivariate analyses; all other independent variables (below the line) were 
added one at a time into the multivariable model to obtain their respective multivariate RR 
The mean values shown in the table are the mean of each specified independent variable per participant over 
the follow-up duration of 18 months. 
a=p≤0.001 b= 0.001˂p ≤0.05  c=0.05˂p≤0.1 d=p>0.1 
 
The only multivariate factor found to be significantly associated with risk of developing an 
incident OI was the mean CD4 cell count. For every unit increase in the mean CD4 cell 
count, the risk of an incident OI decreased by 1% after adjusting for baseline anemia status, 
age and the mean BMI over the duration of follow-up [aRR= 0.99; 95% CI: 0.99 to 1.00, 
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p=0.008]. There was no association between the risk of an incident OI and the mean BMI 
over the duration of follow-up [aRR= 0.89; 95% CI: 0.75 to 1.05] or age [aRR= 0.97; 95% 
CI: 0.92 to 1.01].  
Association of baseline anemia and other factors with all-cause death and incident OIs 
When we considered death and incident OIs as a composite outcome, the presence of baseline 
anemia was associated with a 69% increase in risk of death or an incident OI [aRR= 1.69; 




Table 16: Association of baseline anemia and other factors with all-cause death and/or Incident OIs in HIV-
infected Adults initiating HAART 
 
  Bivariate  Multivariate  
Covariate 
n % died 
or had 
OI Risk Ratio (95% CI) Risk Ratio (95% CI) 
Baseline Anemia   
  Absent  209 5.3 1 - 
Present  191 8.9 1.69 (0.81 to 3.52)d 1.69 (0.85 to 3.37)d 
Mean CD4 count (cells/µl)   0.99 (0.98 to 0.99)a 0.99 (0.98 to 0.99)a 
Age (per year)   0.98 (0.94 to 1.02)d 0.97 (0.95 to 1.02)d 
Sex    
  Male  123 7.3 1 - 
Female  277 6.9 0.94 (0.44 to 2.01)d 1.10 (0.52 to 2.33)d 
Mean BMI   0.97 (0.87 to 1.08)d 1.00 (0.91 to 1.11)d 
Mean PLT   1.00 (0.99 to 1.01)d 1.00 (0.99 to 1.01)d 
Mean WBC   1.03 (0.68 to 1.57)d 1.23 (0.88 to 1.72)d 
Cytopenia status    
  Absent  140 5.7 1 - 
Present  260 7.7 1.35 (0.61 to 2.98)d 0.56 (0.16 to 2.00)d 
Marital Status    
  Not Married  265 7.2 1 - 
Married  135 6.7 0.93 (0.43 to 2.00)d 1.04 (0.51 to 2.11)d 
Employment Status    
  Not Employed 55 5.5 1 - 
Employed  345 7.3 1.33 (0.41 to 4.26)d 0.97 (0.35 to 2.72)d 
Educational Level    
  None  13 7.7 1 - 
Primary  206 7.3 0.95 (0.14 to 6.64)d 0.57 (0.08 to 4.24)d 
Secondary  141 7.1 0.92 (0.13 to 6.66)d 0.57 (0.07 to 4.47)d 
Tertiary  40 5.0 0.65 (0.06 to 6.62)d 0.41 (0.04 to 4.27)d 
a=p≤0.001 b= 0.001˂p ≤0.05  c=0.05˂p≤0.1 d=p>0.1 
The solid line demarcates those independent variables that entered into the final multivariable model (above 
the line) at a p-value cut off of 0.1 at bivariate analyses; all other independent variables (below the line) were 
added one at a time into the multivariable model to obtain their respective multivariate RR 
The mean values shown in the table are the mean of each specified independent variable per participant over 




The only multivariate factor that was significantly associated with death and incident OIs 
after adjusting for the baseline anemia status was the mean CD4 cell count. For every unit 
increase in the mean CD4 cell count over the duration of follow-up, the risk of death and 
incident OIs decreased by 1% [aRR= 0.99; 95% CI: 0.98 to 0.99, p˂0.001]. The risk of death 
and incident OIs decreased by 3% for every one year increase in age [aRR=0.97; 95% CI: 
0.95 to 1.02] and increased by 10% in females compared to males [aRR= 1.10; 95% CI: 0.52 
to 2.33] after adjusting for baseline anemia status and the mean CD4 cell count but none of 
these associations were significant. There was no difference in the risk of death and incident 
OIs with every unit increase in the mean BMI [aRR= 1.00; 95% CI: 0.91 to 1.11] or the mean 
platelet count [aRR=1.00; 95% CI: 0.99 to 1.01] over the duration of follow-up. 
5 Discussion 
5.1 Prevalence of cytopenia at the time of initiating HAART  
The overall prevalence of cytopenia in this study was high at 65% (260/400), with 
anemia occurring in 48%, leucopenia in 24% and thrombocytopenia in 8%. We 
evaluated the types and magnitude of cytopenias in HIV-infected adults at initiation of 
HAART in an urban cohort in Uganda and found a higher prevalence of all 3 forms of 
cytopenia in this population compared to two other studies in HIV-infected individuals 
prior to initiation of HAART; one in South Korea and another, a multicenter study in 
nine countries: Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, the USA and 
Zimbabwe. The baseline prevalence of anemia was 3% in the Korean study and 11.9% 
in the multicenter study; neutropenia occurred in 10% and 14.3 % and 
thrombocytopenia in 2.4% and 7.2% respectively [43, 82]. Apart from the different 
settings of these studies, these differences could be due to different inclusion/exclusion 
criteria used in these studies for example, subjects with severe forms of anemia were 
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excluded from the Korean and multicenter studies thus under-estimating the true 
prevalence or due to different cut-off values used to define the cytopenias.  
Anemia was the most prevalent cytopenia in this study at 48% and this is consistent 
with a systematic review of studies that documented prevalence rates of 35 to 65% in 
individuals in the US and Europe before or at the start of HAART [33, 83] and 18 to 
77% in Africa and Asia [66, 74, 84]. Furthermore these findings are consistent with 
pre-HAART [15, 32] and HAART studies [49, 50] that have shown anemia to be the 
most common cytopenia. Our data show a higher prevalence of anemia compared to 2 
relatively large cohorts: the Therapeutics Research, Education and AIDS Training in 
Asia (TREAT Asia) HIV Observational Database (TAHOD) from the Asia-Pacific 
region [85] and the Development of Antiretroviral Therapy (DART) trial in Uganda 
and Zimbabwe [86]. Anemia was reported in 18.2% (170/932) of those who were tested 
at baseline in the TAHOD cohort and in 12% of the 3,314 participants randomized in 
the DART trial at baseline. The difference in the baseline prevalence of anemia 
between our study population and the TAHOD cohort could be due to different 
ethnicities with the TAHOD cohort being of Asia-Pacific origin and predominantly 
Chinese as well as gender distribution differences between the 2 populations: the 
TAHOD cohort is predominantly male (72%) while our study population was 
predominantly female (65%) thus leading to different gender-based risks for anemia in 
both populations. Our data originate from an urban cohort in Uganda and further show 
a higher prevalence of anemia compared to a rural cohort in Uganda [53]. The 
prevalence of anemia in the rural cohort was 18.9% compared to 48% in our study even 
though lower hemoglobin cut-off values were used to define anemia in the rural cohort 
and CD4 counts were comparable across the two populations. In our study anemia was 
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defined as <12.0g/dl in females vs. <11.0 g/dl in the rural cohort while in males it was 
defined as <13.0 g/dl vs. <12.0g/dl respectively. These differences could be due to 
differences in modifiable factors which may vary between rural and urban populations 
such as dietary factors, alcohol and tobacco use etc., although we could not confirm this 
hypothesis.  
5.2 Correlates of cytopenia in HIV-infected individuals initiating 
HAART 
In our study female sex, lower CD4 cell counts and lower body mass index (BMI) were 
independent predictors of having a cytopenia at baseline. The causative role of HIV in 
vivo in altering the bone marrow microenvironment thus inhibiting hematopoiesis and 
directly resulting in cytopenia is uncertain [13, 18]. Our findings however are 
consistent with other studies that have shown that females are more likely to have 
anemia than males [43, 53, 84] and that have demonstrated an association between low 
CD4 cell count and the presence or development of anemia [67, 83], neutropenia [64, 
87] and thrombocytopenia [87]. The gender-specific differences in cytopenia 
prevalence rates particularly with regard to anemia may be due to additional demands 
in women of reproductive age during menstruation and pregnancy-related events. The 
highest rates of cytopenia occurred in subjects with advanced HIV (CD4 count ˂ 200 
cells/µl). Cytopenias occur more frequently with HIV progression and/or as viral 
replication persists and patients may present with multiple cytopenias [15, 21, 88]. Our 
findings are comparable with those from other studies in developing countries that have 
shown an increase in the prevalence of various forms of cytopenia with advanced HIV-
disease [64, 74, 84, 89]. The prevalence of anemia in this study was 49% in subjects 
with CD4 counts below 200 (n=300) while for subjects with higher CD4 counts 
(n=100), it was 43%. Similarly subjects with CD4 counts below 200 had a higher 
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prevalence of leucopenia than those with higher CD4 counts (27% versus 17% 
respectively). Finally the prevalence of thrombocytopenia was similar for both CD4 
categories (8.3% versus 8% respectively). However, these differences by CD4 category 
<200 or ≥ 200 were statistically significant only for leucopenia prevalence. We 
demonstrated that among other factors such as BMI and age, hemoglobin levels 
significantly increased with high CD4 cell count. This is consistent with other studies 
that have shown an association between leucopenia and low CD4 counts with anemia 
[14, 46, 67]. The association between low CD4 cell count and anemia or leucopenia 
may be due to the dysregulatory effect of HIV on the function of early hematopoietic 
progenitor cells through the viral accessory protein Negative factor [21]. 
The main factors associated with having baseline anemia in this study were female sex 
and low BMI. Similar risk factors for anemia were demonstrated by the PEARLS 
study, a multicenter comparative analysis of pre-treatment hematological abnormalities 
in HIV-infected individuals [43] and the DART trial [86].Women constitute a growing 
at-risk subpopulation for HIV infection and the prevalence of anemia in HIV-infected 
women has been evaluated in 2 urban cohorts in the US [90]. In the HER study, the 
authors compared the prevalence and cumulative incidence of anemia in 797 HIV-
positive women and 389 HIV-negative women and found that the prevalence was 
higher by 13% in the HIV-positive cohort than the HIV-negative cohort [38]. The 
Women’s Interagency HIV Study (WIHS) evaluated anemia in HIV-infected women 
and found a prevalence of 37% in the HIV-positive women and 17% in the HIV-
negative women [67]. Interestingly, even subjects with a normal BMI had a higher 
prevalence of anemia [PR=0.43; 95%CI: 0.19-0.99, p=0.048] than those who were 
overweight [PR=0.17; 95%CI: 0.07-0.41, p˂0.001]. The association of anemia with 
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low BMI is possibly due to nutrient deficiencies of iron, folate and vitamin B12 and to 
chronic malnutrition [84]. Consequently improvement of social and nutritional 
conditions may reduce anemia prevalence and incidence in resource-limited settings 
[89]. We did not exclude malaria as well as hereditary causes of anemia in this 
population such as thalassemias and sickle-cell disease as possible causes of anemia in 
our study. 
The main factor associated with having baseline leucopenia in this study was low CD4 
cell count suggesting that the stage of HIV infection may contribute to baseline 
leucopenia. The most clinically relevant subtype of leucopenia is neutropenia. The 
PEARLS study also found that neutropenia was associated with low CD4 cell count 
among other factors such as the platelet count, hemoglobin, sex, ethnicity and 
geographical location [43]. Neutropenia in HIV-infection may result from decreased 
production of granulocyte colony-stimulating growth factor (G-CSF) and 
autoimmunity. The presence of neutropenia in HIV-infection predisposes to infections 
such as bacteremia and effective HAART may reduce the incidence of neutropenia and 
thus of bacterial infections [91]. 
Baseline thrombocytopenia was the least frequent of all the forms of cytopenia and was 
associated with sex and HAART status at enrolment. Females were less likely to have 
thrombocytopenia compared to males and those with HAART experience were less 
likely to have thrombocytopenia than those who were HAART naïve. These findings 
are similar to the PEARLS study which demonstrated a lower prevalence of 
thrombocytopenia compared to neutropenia and anemia and that males were more 
likely to have thrombocytopenia in addition to other risk factors such chronic hepatitis 
B infection and neutropenia [43]. 
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5.3 Trends in hematological parameters in HIV-infected adults on 
HAART 
We found that the use of HAART was associated with an increase in hemoglobin levels 
during one and a half years of follow-up and that this hemoglobin response was 
associated with BMI, CD4 cell count and age. Our data demonstrate a hemoglobin 
response that is consistent with other studies that have shown that the use of HAART 
for at least 6 months is associated with an increase in hemoglobin and a decreased 
likelihood of anemia [14, 33, 35, 92, 93]. In 2 urban cohort studies, one that examined 
the impact of HAART on anemia in HIV-infected women (the Human 
Immunodeficiency Virus Epidemiological Research (HER) study) [94] and another that 
documented the risk factors and natural history of HIV-infection in injection drug users 
(the AIDS Linked to Intravenous Experiences (ALIVE) study) [14], Semba et al 
demonstrated reductions in anemia after one year of HAART of approximately 32% 
and 17% respectively in these highly-selected urban populations. Our study extends 
these observations to show a 50% reduction in anemia after one year of HAART in a 
more heterogeneous, urban population with fewer HAART regimen options compared 
to these 2 cohorts. There are several mechanisms which may account for the 
improvement of anemia following HAART initiation. Anemia of chronic disease 
accounts for a large proportion of anemia during HIV infection as a result of the 
chronic inflammation during HIV infection and the myriad of opportunistic 
infections[14]. Anemia of chronic disease is defined as anemia occurring in association 
with infectious diseases, neoplasms and inflammatory conditions presenting with 
hypoferremia (iron deficiency) in the presence of adequate storage iron and the absence 
of any other known cause of anemia [7, 95]. Its pathogenesis is not well understood but 
is thought to result from three processes: shortened erythrocyte survival, failure of bone 
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marrow erythropoiesis to compensate the increased demand during infection and 
inflammation  and reduced erythropoietin production, a hormone that is essential for 
the survival, proliferation and differentiation of erythroid progenitor cells [96, 97] . 
HAART has demonstrated the potential to reduce the occurrence of several 
opportunistic infections [91, 98-101]. HAART also appears to reverse the cytokine 
dysregulation observed during HIV infection and to control monocyte activation thus 
reducing the expression of certain cytokines like tumor necrosis factor (TNF) alpha 
which may play a role in the suppression of erythropoiesis [102-104]. Another 
mechanism by which HAART may improve anemia is through the reduction of chronic 
diarrhea and enteric infections such as microsporidiosis and cryptosporidiosis [98, 100] 
thus improving absorption and metabolism of micronutrients that are essential for 
erythropoiesis such as vitamin A, vitamin B12, folate and iron [14, 98, 105]. In this 
present study, most patients (92%) received AZT-based HAART and yet demonstrated 
a consistent hemoglobin increase throughout the follow-up period. A study comparing 
the incidence of anemia in AZT-naïve patients initiating AZT-containing HAART and 
those initiating non-AZT based HAART, Curkendall found that patients on AZT-based 
HAART had a greater risk of developing new anemia or worsening anemia compared 
to those on non-AZT based HAART [93]. In contrast, Kiragga et al demonstrated that 
the majority of patients initiating AZT-containing HAART experienced an 
improvement in hemoglobin suggesting that baseline severe anemia should not be the 
only determining criterion to avoid use of AZT in patients initiating HAART in 
resource-poor settings [54]. In a study undertaken to document the correlates of anemia 
in an urban HIV-infected population in the US as well as to investigate the relationship 
between testosterone levels and prevalence of anemia, it was found that there was no 
significant association between current zidovudine use and anemia [63]. Furthermore, 
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in comparison to patients without anemia in this US cohort, anemic patients were more 
likely to have more advanced HIV disease, lower recent and nadir CD4 cell counts and 
higher recent and peak viral loads. Effective use of HAART irrespective of whether 
zidovudine is part of the regimen is associated with improvement in hemoglobin levels 
[46].  
There was an overall reduction in the prevalence of all grades of anemia observed in 
our study but not a complete correction to normal hemoglobin levels after one and a 
half years on HAART. It is possible that other contributing factors to the persistence of 
anemia despite HAART in this setting are due to micronutrient deficiencies e.g iron and 
vitamin deficiencies. However, Semba et al also found that 25% of the women in the 
HER study were still anemic after one year on HAART [38]. Studies have shown that 
even though the introduction of HAART has led to significant reductions in the 
prevalence of severe anemia, mild to moderate anemia persists in some individuals [14, 
46, 65, 94]. In a large prospective study of HIV-infected adults attending the Infectious 
Diseases Institute clinic at the time when HAART was being rolled out in Uganda, 
HAART initiation led to increased hemoglobin levels for the majority of patients but 
3.5% developed early severe anemia within 6 months of HAART initiation [54]. 
Kiragga et al attributed this to concurrent tuberculosis (TB), a low MCV and baseline 
severe anemia. The persistence of mild to moderate forms of anemia or hemoglobin 
levels between 10 and 14g/dl is clinically significant because it has been associated 
with decreased quality of life measured by functional status and fatigue [46, 106, 107]. 
An elevation of the MCV was observed in our study throughout the follow-up period 
from a mean of 87.5 femtolitres (fl) at the time of recruitment into the study to a mean 
of 102.9 fl after 18 months. Macrocytosis (MCV ˃100fl) is estimated to be about 2% in 
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the general population [108] and has been described in HIV-infected populations in 
both zidovudine-exposed and zidovudine-naïve patients. Macrocytosis is thought to 
result from the use of thymidine analogues that is AZT and d4T but also with the use of 
lamivudine [9, 11, 109, 110]. Changes in the MCV specifically macrocytosis in HIV-
positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs) are used as 
surrogate markers for adherence to HAART [111]. Furthermore, about 40% of patients 
who develop macrocytosis have co-morbid anemia [108]. In our study, 12 out of the 17 
patients (70%) with macrocytosis at baseline were anemic. 
The mean white blood cell (WBC) and platelet counts in the present study at the start 
and throughout the follow-up period were generally higher than those observed by 
Servais et al. in  HIV-infected patients from Luxemburg and Belgium who were 
treatment naïve (Luxemburg sub-population) and then observed for one year while on 
HAART (Belgium sub-population) [65]. WBC counts in our study rose from a mean of 
3600 to 3720 cells/µl compared to 2260 to 3600 cells/µl in the 2 European sub-
populations. Interestingly the platelet recovery in our cohort was not sustained 
throughout the follow-up period; the mean platelet count rose from 252,000 to 264,000 
cells/µl at 6 months and then gradually decreased to 257,000 cells/µl at 18 months. This 
is in contrast to the findings from the longitudinal study by Servais et al where platelets 
steadily and significantly increased from 110,000 to ˂180,000 cells/µl at 24 months.  
These data suggest that HAART may induce changes in clinically relevant 
hematological parameters leading to the correction of some abnormalities such as 
anemia and potential worsening of other parameters like the MCV [82, 94], the MCHC 
and in some populations such as this cohort, the platelet count. 
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5.4 Association of baseline anemia and other factors with HIV-disease 
progression and/or death in adults initiating HAART 
We found that baseline anemia and the mean CD4 cell count over the duration of 
follow-up were the main factors associated with the risk of disease progression and/or 
death in this population independent of age, sex and body mass index among other 
factors. Our findings are similar to those of a cohort of HIV-infected women in 
Tanzania in whom O’Brien et al. showed an association of anemia with disease 
progression and both all-cause mortality and AIDS-related mortality [62]. In our study 
baseline anemia was associated with a 5-fold increased risk of death while every unit 
increase in the mean CD4 cell count was associated with a 1% decrease in the risk of 
death. In contrast, O’Brien et al. did not find a significant association between baseline 
hemoglobin and time to death or disease progression possibly because only one 
measure of hemoglobin may not predict long-term risk of disease progression and 
furthermore, a single measure of hemoglobin is more strongly associated with disease 
progression in advanced HIV than in early stage disease as in their study population of 
asymptomatic women [62]. These data are however consistent with several other 
studies in developed countries that have demonstrated that hemoglobin level and/or 
anemia are strong independent predictors of morbidity and mortality in HIV-infected 
individuals [32-34, 37, 48, 61, 62] as well as progression to AIDS/opportunistic 
infections [71, 112]. The EuroSIDA study for example, is a prospective study of HIV-
infected patients in 70 centres across Europe, Argentina and Israel that have provided 
data on consecutive patients seen in the outpatient clinic and enrolled into 5 cohorts at 
various time points (that is from 1994 to 2001) [33, 61, 113, 114]. Lundgren et al 
showed that despite the fact that the mechanism underlying why hemoglobin was a 
strong prognostic marker was not known, mild and severe anemia were independently 
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associated with clinical disease progression and that the relative hazard of death 
increased markedly for HIV-infected anemic patients enrolled in the EuroSIDA study 
compared to those without anemia [61]. The evidence from our study is consistent with 
the literature that has shown an association between a) HIV-related anemia and various 
factors such as female sex, CD4 cell counts below 200 cells/µl, ethnicity and 
zidovudine use [32, 33, 61, 67] and b) the presence of anemia and decreased survival in 
these patients despite the differences in patient population, hemoglobin cut-offs used to 
define anemia and available HAART regimens [22, 33, 34, 37, 61, 67, 93, 115-117]. 
We have further shown that initiation of HAART was associated with recovery from 
anemia and this is consistent with the findings from other studies [14, 66, 94]. In 
developed countries, recombinant human erythropoietin (epoietin alfa) is recommended 
for the treatment of HIV-associated anemia as a routine practice if correctable causes of 
anemia have been ruled out [118-120]. Behler et al further showed a negative 
association between anemia and the use of supplemental androgens and hypothesized 
that supplemental androgens stimulated erythropoietin production thus improving 
hemoglobin levels [63]. In these settings the use of epoietin alfa has been associated 
with improved survival [34] and quality of life [121, 122] however, because of its cost 
it is neither routinely available nor a feasible public health intervention in resource-
limited settings such as Uganda.  
5.5 Strengths and limitations of the study 
This study provides a comparative analysis of the prevalence estimates and correlates 
of all forms of cytopenia in HIV-infected adults at initiation of HAART in Uganda. It 
further demonstrates the trend in hematological parameters in HAART-treated 
individuals in a resource-limited setting and thus suggests these parameters as surrogate 
markers for monitoring treatment response in these settings. 
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This study had the limitation of observational studies that these data do not confirm a 
causal pathway between hematological abnormalities and clinical outcomes with 
HAART. Furthermore, the statistical power of these analyses, being nested within a 
larger randomized clinical trial of multivitamin supplementation, were bound by the 
parent study and any losses to follow-up.  
We did not adjust for the intervention that is multivitamin supplementation versus 
placebo because the intervention data were not accessible at the time of these analyses 
due to logistical and trial-related reasons. However, we do not think that this would 
have affected our results since patients were randomly allocated to either treatment 
arm. 
The various causes of cytopenias and especially anemia could not be assessed. Bone 
marrow biopsies were not done as part of the parent study protocol therefore exclusion 
of low cell counts due to disorders of production could not be confirmed. 
The assessment of red blood cell indices was incomplete without film reports, ferritin 
and transferrin measurements thus we were not able to differentiate causes of anemia 
due to problems of iron storage and transportation. 
6 Conclusion 
 The prevalence of baseline cytopenias was high at 65% and in particular 48% of our 
study population was anemic. Our findings have shown that initiation of HAART 
improves hemoglobin levels and corrects anemia even when AZT-based HAART is used 
as a first-line regimen in resource-limited settings. Other studies have shown that the use 
of protease inhibitors (PIs) in first-line regimens may provide added benefits such as less 
hematologic toxicity and reverse HIV-induced inhibition of hematopoiesis [65]. 
However, the feasibility of PI-based HAART at a public health level especially in 
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resource-limited settings needs further investigation in terms of cost-effectiveness and 
future options for long-term therapy. Other selected hematological parameters may have 
various responses to HAART with some improving such as the white blood cell count 
and others potentially worsening such as the platelet count. The only significant 
predictors of cytopenias at the initiation of HAART are sex, body mass index and CD4 
cell count. Thus screening for clinically relevant hematological parameters prior to 
initiation of HAART as well as during HAART must be prioritized and interventions 
should take into consideration gender-based risks, nutritional interventions and other 
contributing factors to immune suppression. Finally, despite a 50% reduction in anemia 
prevalence in our study, more than one fifth of patients did not reach normal hemoglobin 
levels while on HAART. This means that additional interventions need to be identified in 
the subset of patients in whom hematological abnormalities persist with HAART because 
these patients are at risk for disease progression and death particularly the anemic, 
wasted patient with persistently low or declining CD4 cell counts. In summary, these 
findings have implications for screening for cytopenias at entry into HIV care, the choice 
of an optimal initial HAART regimen and monitoring of these parameters while on 
HAART so as to intervene where the abnormalities may be potentially reversible. 
Randomized controlled trials of HAART are needed to confirm the causal pathway 
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